Chryseobacterium meningosepticum infection: Antibiotic susceptibility and risk factors for mortality

Journal of Microbiology, Immunology and Infection

Volumn 41, Issue 2, 2008, Pages 137-144

  Hung, Po Pin ^a   Lin, Yu Hui ^a   Lin, Chin Fu ^a   Liu, Meei Fang ^a   Shi, Zhi Yuan ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Antimicrobial susceptibility tests; Chryseobacterium; Mortality; Risk factors

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFAZOLIN; CEFEPIME; CEFOPERAZONE; CEFPIROME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; LEVOFLOXACIN; MINOCYCLINE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TIMENTIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; CHRYSEOBACTERIUM MENINGOSEPTICUM; CLINICAL ARTICLE; DEMOGRAPHY; FEMALE; FISHER EXACT TEST; HUMAN; HYPOALBUMINEMIA; MALE; MEDICAL INFORMATION; MEDICAL PARAMETERS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; PULSE RATE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHRYSEOBACTERIUM; CIPROFLOXACIN; FEMALE; FLAVOBACTERIACEAE INFECTIONS; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OFLOXACIN; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; TREATMENT OUTCOME;

EID: 48649107720     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Güngör S, Ozen M, Akinci A, Durmaz R. A Chryseobacterium meningosepticum outbreak in a neonatal ward. Infect Control Hosp Epidemiol. 2003;24:613-7.
2. Tekerekoglu MS, Durmaz R, Ayan M, Cizmeci Z, Akinci A. Analysis of an outbreak due to Chryseobacterium meningosepticum in a neonatal intensive care unit. New Microbiol. 2003;26:57-63.
3. Hoque SN, Graham J, Kaufmann ME, Tabaqchali S. Chryseobacterium (Flavobacterium) meningosepticum outbreak associated with colonization of water taps in a neonatal intensive care unit. J Hosp Infect. 2001 ;47: 188-92.
4. Bloch KC, Nadarajah R, Jacobs R. Chryseobacterium meningosepticum: an emerging pathogen among immunocompromised adults. Report of 6 cases and literature review. Medicine (Baltimore). 1997;76:30-41.
5. Hsueh PR, Teng LJ, Yang PC, Ho SW, Luh KT. Susceptibilities of Chryseobacterium indologenes and Chryseobacterium meningosepticum to cefepime and cefpirome. J Clin Microbiol. 1997;35:3323-4.
6. Woodford N, Palepou MF, Babini GS, Holmes B, Liver-more DM. Carbapenemases of Chryseobacterium (Flavobacterium) meningosepticum: distribution of blaB and characterization of a novel metallo-beta-lactamase gene, blaB3, in the type strain, NCTC 10016. Antimicrob Agents Chemother. 2000;44:1448-52.
7. Chang JC, Hsueh PR, Wu JJ, Ho SW, Hsieh WC, Luh KT. Antimicrobial susceptibility of Flavobacteria as determined by agar dilution and disk diffusion methods. Antimicrob Agents Chemother. 1997;41:1301-6.
8. Kirby JT, Sader HS, Walsh TR, Jones RN. Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp: report from the SENTRY Antimicrobial Surveillance Program (1997-2001). J Clin Microbiol. 2004;42:445-8.
9. Fraser SL, Jorgensen JH. Reappraisal of the antimicrobial susceptibilities of Chryseobacterium and Flavobacterium species and methods for reliable susceptibility testing. Antimicrob Agents Chemother. 1997;41:2738-41.
10. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. 6th ed. NCCLS document M7-A6. Wayne, PA: National Committee for Clinical Laboratory Standards; 2003.
11. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing. 13th informational supplement. NCCLS document M100-S13. Wayne, PA: National Committee for Clinical Laboratory Standards; 2003.
12. Lin PY, Chu C, Su LH, Huang CT, Chang WY, Chiu CH. Clinical and microbiological analysis of bloodstream infections caused by Chryseobacterium meningosepticum in nonneonatal patients. J Clin Microbiol. 2004;42: 3353-5.
13. Bellais S, Poirel L, Naas T, Girlich D, Nordmann P. Genetic-biochemical analysis and distribution of the Ambler class A beta-lactamase CME-2, responsible for extended-spectrum cephalosporin resistance in Chryseobacterium (Flavobacterium) meningosepticum. Antimicrob Agents Chemother. 2000;44:1-9.
14. Hawley HB, Gump DW. Vancomycin therapy of bacterial meningitis. Am J Dis Child. 1973;126:261-4.
15. Chiu CH, Waddingdon M, Greenberg D, Schreckenberger PC, Carnahan AM. Atypical Chryseobacterium meningosepticum and meningitis and sepsis in newborns and the immunocompromised, Taiwan. Emerg Infect Dis. 2000;6:481-6.